Matinas BioPharma to Present at the MicroCap Conference
September 25 2018 - 08:00AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a
clinical-stage biopharmaceutical company focused on enabling
targeted intracellular delivery of life-changing medicines using
its proprietary lipid nano-crystal (LNC) platform technology,
announced today that Jerome D. Jabbour, Chief Executive Officer,
will present at the MicroCap Conference on Monday, October 1, 2018
at 8:30 AM ET in New York, NY.
As part of his presentation, Mr. Jabbour will
provide a corporate update and will discuss the Company’s
differentiated LNC drug delivery platform which offers an
intracellular drug delivery solution with potential advantages for
a range of therapeutics, including small molecules, nucleic acid
polymers, proteins, peptides, vaccines, as well as the targeted
delivery of gene editing technologies. He will review the
Company's lead platform-validating product candidate, MAT2203, and
its streamlined and risk-mitigated development program focused on a
potential pivotal Phase 2 trial of MAT2203 for the prevention of
invasive fungal infections (IFIs) in patients with acute
lymphoblastic leukemia, an area of significant unmet medical
need. Mr. Jabbour will also address the Company’s second LNC
product candidate, MAT2501, which, as potentially the first orally
available aminoglycoside, is being positioned as a differentiated
therapy for the treatment of non-tuberculous mycobacterium (NTM)
infections, as well as other acute bacterial infections.
Additionally, Mr. Jabbour will discuss MAT9001,
the Company’s proprietary prescription-only omega-3 fatty
acid-based composition under development for hypertriglyceridemia
(TG>500 mg/dL), which has demonstrated statistically significant
superiority versus Vascepa® (icosapent ethyl) in reducing serum
triglycerides, total- and non-HDL-cholesterol, apolipoproteins and
PCSK9 levels. MAT9001 is a next-generation omega-3 fatty acid
composition, comprising docosapentaenoic acid (DPA), a potent but
less prevalent omega-3 fatty acid with very unique properties, and
other omega-3 fatty acids. MAT9001 was developed based on the
newest scientific advancements in the field, incorporating and
building upon the knowledge of almost 40 years of scientific
research in the omega-3 discipline. Given recently announced
developments in the cardiovascular space and the potential
best-in-class data generated by MAT9001 to date, Matinas is well
prepared to be opportunistic in evaluating strategic alternatives
to further develop and commercialize MAT9001 on a global and/or
regional basis.
In addition to the presentation, management will
also be available to participate in one-on-one meetings with
qualified members of the investor community who are registered to
attend the conference.
A live audio webcast of the presentation will be
available on the Events page of the Investors section of the
Company’s website (www.matinasbiopharma.com). A webcast replay will
be accessible for 90 days following the live presentation.
About Matinas BioPharma Matinas
BioPharma is a clinical-stage biopharmaceutical company focused on
developing innovative medicines using its lipid nano-crystal (LNC)
platform delivery technology. The Company's proprietary, disruptive
technology utilizes lipid-crystal nano-particle cochleates to
nano-encapsulate small molecules, oligonucleotides, vaccines and
other medicines potentially making them safer, more tolerable, less
toxic and orally bioavailable.
The Company's lead anti-fungal product
candidate, MAT2203, positions Matinas BioPharma to become a leader
in the safe and effective delivery of anti-infective therapies
utilizing its proprietary LNC formulation technology.
For more information, please visit
www.matinasbiopharma.com and connect with the Company on Twitter,
LinkedIn, Facebook, and Google+.
Forward Looking Statements:
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including those relating to the Company's anticipated capital and
liquidity needs, strategic focus and the future development of its
product candidates, including MAT2203, the anticipated timing of
regulatory submissions, the anticipated timing of clinical studies,
the anticipated timing of regulatory interactions, the Company’s
ability to identify and pursue development and partnership
opportunities for its products or platform delivery technology on
favorable terms, if at all, and the ability to obtain required
regulatory approval and other statements that are predictive in
nature, that depend upon or refer to future events or conditions.
All statements other than statements of historical fact are
statements that could be forward-looking statements.
Forward-looking statements include words such as "expects,"
"anticipates," "intends," "plans," "could," "believes," "estimates"
and similar expressions. These statements involve known and unknown
risks, uncertainties and other factors which may cause actual
results to be materially different from any future results
expressed or implied by the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, our ability to obtain
additional capital to meet our liquidity needs on acceptable terms,
or at all, including the additional capital which will be necessary
to complete the clinical trials of our product candidates; our
ability to successfully complete research and further development
and commercialization of our product candidates; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to maintain and derive
benefit from the Qualified Infectious Disease Product (QIDP),
Orphan and/or Fast Track designations for MAT2203, which does not
change the standards for regulatory approval or guarantee
regulatory approval on an expedited basis, or at all; our ability
to protect the Company's intellectual property; the loss of any
executive officers or key personnel or consultants; competition;
changes in the regulatory landscape or the imposition of
regulations that affect the Company's products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma's
product candidates are all in a development stage and are not
available for sale or use.
Investor ContactJenene ThomasJenene Thomas
Communications, LLCPhone: +1 (833) 475-8247Email:
mtnb@jtcir.com |
Media
ContactEliza Schleifstein Scient Public RelationsPhone: +
1 (917) 763-8106 Email: eliza@scientpr.com |
|
|
Source: Matinas BioPharma Holdings, Inc.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2023 to Mar 2024